LSD, Addiction and the Return of Deep Psychological Work
LSD Is Having a Second Life in Therapy
For decades, LSD occupied a strange position in the public imagination: culturally iconic, clinically taboo and largely absent from legitimate psychiatric research.
That is changing.
In September 2026, Definium Therapeutics reported positive results from a second Phase 3 trial of its LSD-based treatment for generalised anxiety disorder. The company reported a statistically significant placebo-adjusted improvement at 12 weeks and is preparing for a potential regulatory submission in 2027. If that programme continues successfully, LSD could become one of the first classic psychedelics to enter mainstream pharmaceutical medicine for anxiety.
But the more interesting story is not simply that LSD may be coming back.
It is what we may have forgotten about it.
LSD was never simply another psychedelic
Long before the current psychedelic renaissance, LSD was being explored within psychiatry and psychotherapy.
One approach, known as psycholytic therapy, used LSD within an ongoing psychotherapeutic relationship. Rather than treating the psychedelic experience as an isolated event, practitioners worked with repeated sessions, preparation, therapeutic presence and the material that emerged during and between sessions.
A 2026 realist review revisited literature covering psycholytic therapy from 1948 to 1995, examining more than 4,600 sessions. The review found that historical approaches varied considerably, but identified several recurring features associated with better outcomes: substantial preparation, a strong therapeutic relationship, continuous therapist presence and a flexible rather than rigid therapeutic approach.
The historical evidence has obvious limitations. Much of it predates modern clinical-trial standards, and the review itself argues that further research is needed.
But it raises an important question.
What if LSD's therapeutic potential was never adequately understood because the field stopped studying the whole model before it had finished studying the medicine?
The new LSD story is not only about anxiety
Today's research is naturally focused on conditions that can be measured within conventional clinical frameworks.
Anxiety is one.
But the experience of LSD has always raised questions that extend beyond symptom reduction.
What happens when ordinary patterns of thought become less rigid?
What happens when someone who normally analyses everything is temporarily unable to maintain the same level of cognitive control?
What happens when a person's familiar understanding of themselves becomes less fixed?
These questions matter particularly for people whose lives are highly structured around achievement, responsibility and control.
For an executive operating under sustained pressure, the problem may not simply be that they have too much work.
It may be that their entire identity has become organised around performance.
The capacity to anticipate, analyse, optimise and remain in control can be enormously valuable in professional life. It can also become difficult to switch off.
Psychedelic experiences are sometimes discussed in terms of “letting go”, but that phrase can be too simplistic. The more interesting possibility is that temporarily loosening familiar patterns of cognition may allow a person to encounter aspects of themselves that are normally filtered out by those same patterns.
That does not make LSD a treatment for burnout.
It does, however, make the relationship between psychedelic states and highly cognitive, high-control ways of living worth examining.
LSD and the question of alcohol
The addiction story is even more intriguing.
LSD is often overlooked in contemporary conversations about psychedelic-assisted treatment for addiction, partly because the modern spotlight has moved towards psilocybin, ketamine and ibogaine.
That is curious given LSD's historical relationship with alcohol treatment.
LSD was studied for alcoholism extensively during the 1960s. The historical literature is mixed, and some controlled studies failed to demonstrate superiority of LSD treatment over comparison conditions.
But a later systematic review and meta-analysis found that, across the available randomised controlled trials, LSD was associated with greater odds of abstinence or substantial reduction in drinking at the first recorded follow-up. The authors also highlighted a major limitation: the LSD trials were old, most dated from 1966–1970, and several had important methodological weaknesses.
So this is not a case for declaring LSD an established treatment for alcohol use disorder.
It is something more interesting: an old therapeutic signal that deserves better contemporary research.
A 2026 review of psychedelic-assisted treatment for substance-use disorders identified six recurring psychological domains across the literature: emotional processing, insight and meaning, self-experience and identity, peak or mystical experiences, relationships, and motivation and behavioural regulation.
Those mechanisms are particularly interesting in alcohol addiction.
Because alcohol dependence is not always experienced simply as a problem of consumption.
For some individuals, alcohol becomes intertwined with identity, relationships, emotional regulation, social confidence, reward, avoidance and the management of difficult internal states.
Changing drinking behaviour may therefore require more than suppressing a craving.
It may require a different relationship with the person who is doing the drinking.
That is precisely where psychedelic research becomes intellectually interesting.
From craving to identity
One of the more compelling developments in psychedelic addiction research is the increasing attention being paid to identity and meaning.
The question becomes less: “How do we stop someone drinking?”
and more: “What function has drinking come to serve in this person's life?”
That distinction matters.
For a senior executive, entrepreneur, artist or other high-performing individual, alcohol may occupy a very different psychological role from the one assumed by a conventional addiction model.
It might be associated with decompression after prolonged cognitive effort. It might function as social lubrication. It might mark the boundary between work and private life. It might provide temporary relief from responsibility or emotional constraint.
Or it might simply have become automatic.
A psychedelic experience does not automatically resolve any of those patterns.
But it may provide a state in which normally entrenched assumptions can be examined from a different perspective.
That is one reason LSD deserves more attention in the addiction conversation.
The psychospiritual dimension
There is another part of the LSD story that is increasingly difficult to ignore.
Not everyone who seeks psychedelic work is trying to treat a diagnosis.
Some are trying to understand their lives.
A person may arrive at psychedelic work after years of professional achievement and discover that the question is no longer “How can I perform better?” but “What is all of this for?”
That can involve mortality, relationships, purpose, spirituality, identity and the gap between external success and internal experience.
These questions do not fit neatly into a clinical outcome measure.
They are nevertheless part of why some people seek psychedelic experiences in the first place.
The current research conversation is beginning to recognise this. The recent review of psychedelic-assisted treatment for substance-use disorders, for example, identifies meaning, self-experience, identity and values alongside more familiar behavioural mechanisms.
This does not mean psychedelic therapy should be presented as a shortcut to spiritual enlightenment.
It means that the psychological territory opened by psychedelic states can be considerably broader than symptom reduction.
And LSD, with its long duration and distinctive phenomenology, occupies an unusual place within that territory.
A return — but not a rewind
The resurgence of interest in LSD should not mean simply resurrecting the 1960s.
The historical research is valuable precisely because it gives contemporary researchers questions to revisit.
What did earlier practitioners understand about therapeutic relationships that modern protocols may have overlooked?
Which aspects of psycholytic therapy were genuinely useful?
Which were products of their era?
How should LSD-assisted work differ for someone seeking help with addiction compared with someone exploring longstanding psychological patterns?
And how might the experience differ again for a high-performing individual whose central difficulty is not dysfunction, but an increasingly narrow way of living?
These are much more interesting questions than whether LSD is “back”.
It never really disappeared.
What is returning is the willingness to investigate what it might actually be capable of doing within a carefully constructed therapeutic context.
The next chapter of LSD research may therefore be less about rediscovering a molecule than rediscovering the depth of psychological work that can surround it.
For anyone considering psychedelic work, that distinction matters.
The substance is only one part of the equation.
The person, the intention, the therapeutic relationship, the environment and the wider programme all shape what becomes possible.
